Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link
Dow Jones Industrial Average
) is trading up 86 points (+0.5%) at 15,986 as of Thursday, Nov 21, 2013, 10:35 a.m. ET. During this time, 76.5 million shares of the 30 Dow components have changed hands vs. an average daily trading volume of 380.5 million. The NYSE advances/declines ratio sits at 2,003 issues advancing vs. 833 declining with 128 unchanged.
- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
Friday, November 22, 2013 is the ex-dividend date for Dow component
). Owners of shares as of market close today will be eligible for a dividend of 66 cents per share. At a price of $95.25 as of 10:35 a.m. ET, the dividend yield is 2.8% compared to the average Dow component yield of 2.5%.
The average volume for Johnson & Johnson has been 7.5 million shares per day over the past 30 days. Johnson & Johnson has a market cap of $267.64 billion and is part of the health care sector and drugs industry. Shares are up 35.3% year to date as of Wednesday's close.
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. The company has a P/E ratio of 21.2, equal to the average drugs industry P/E ratio.
- Practice your dividend trading strategies and win cash in our stock game.
TheStreet Ratings rates Johnson & Johnson as a
. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, good cash flow from operations and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.
- You can view the full Johnson & Johnson Ratings Report.